Do analysts recommend MYNZ or BCAB?

BioAtla has a consensus target price of $200.00, indicating a potential upside of 5,081.35%. Given BioAtla's stronger consensus rating and higher probable upside, analysts plainly believe BioAtla is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 BioAtla 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is MYNZ or BCAB more profitable?

Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A BioAtla N/A N/A -325.64%

Is BCAB or CLRB more profitable?

BioAtla's return on equity of 0.00% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -325.64% Cellectar Biosciences N/A -349.24% -153.18%

Which has preferable earnings and valuation, KZIA or BCAB?

Novogen has higher earnings, but lower revenue than BioAtla. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 785.40 -$13.41M N/A N/A BioAtla $2M 3.20 -$59.61M -$41.72 N/A

Is KZIA or BCAB more profitable?

Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A BioAtla N/A N/A -325.64%

Do analysts rate BCAB or TPST?

BioAtla presently has a consensus target price of $200.00, suggesting a potential upside of 5,081.35%. Given BioAtla's stronger consensus rating and higher probable upside, research analysts plainly believe BioAtla is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is BCAB or TPST more profitable?

BioAtla's return on equity of 0.00% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -325.64% Tempest Therapeutics N/A -355.61% -121.21%

Do analysts rate XCUR or BCAB?

BioAtla has a consensus price target of $200.00, suggesting a potential upside of 5,081.35%. Given BioAtla's stronger consensus rating and higher probable upside, analysts clearly believe BioAtla is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioAtla 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is XCUR or BCAB more profitable?

BioAtla's return on equity of 0.00% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% BioAtla N/A N/A -325.64%

BioAtla (BCAB) Competitors

$3.86 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$3.80 -0.05 (-1.42%)

As of 06/12/2026 06:42 PM Eastern

Compare

BCAB vs. MYNZ, CLRB, KZIA, TPST, and XCUR

Should you buy BioAtla stock or one of its competitors? MarketBeat compares BioAtla with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioAtla include Mainz Biomed (MYNZ), Cellectar Biosciences (CLRB), Novogen (KZIA), Tempest Therapeutics (TPST), and Exicure (XCUR). These companies are all part of the "pharmaceutical products" industry.

How does BioAtla compare to Mainz Biomed?

Mainz Biomed (NASDAQ:MYNZ) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

In the previous week, BioAtla had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for BioAtla and 0 mentions for Mainz Biomed. BioAtla's average media sentiment score of 1.87 beat Mainz Biomed's score of 0.00 indicating that BioAtla is being referred to more favorably in the news media.

Company	Overall Sentiment
Mainz Biomed	Neutral
BioAtla	Very Positive

BioAtla has a consensus target price of $200.00, indicating a potential upside of 5,081.35%. Given BioAtla's stronger consensus rating and higher probable upside, analysts plainly believe BioAtla is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Mainz Biomed has higher earnings, but lower revenue than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	23.75	-$21.65M	-$65.60	N/A
BioAtla	$2M	3.20	-$59.61M	-$41.72	N/A

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
BioAtla	N/A	N/A	-325.64%

Mainz Biomed has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, BioAtla has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

77.2% of BioAtla shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by company insiders. Comparatively, 9.3% of BioAtla shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

BioAtla beats Mainz Biomed on 9 of the 14 factors compared between the two stocks.

How does BioAtla compare to Cellectar Biosciences?

BioAtla (NASDAQ:BCAB) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 9.3% of BioAtla shares are owned by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

BioAtla's return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-325.64%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Cellectar Biosciences has lower revenue, but higher earnings than BioAtla. Cellectar Biosciences is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	3.20	-$59.61M	-$41.72	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

BioAtla has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

BioAtla currently has a consensus target price of $200.00, suggesting a potential upside of 5,081.35%. Cellectar Biosciences has a consensus target price of $11.00, suggesting a potential upside of 393.27%. Given BioAtla's higher probable upside, equities analysts plainly believe BioAtla is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Cellectar Biosciences had 1 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for Cellectar Biosciences and 1 mentions for BioAtla. BioAtla's average media sentiment score of 1.87 beat Cellectar Biosciences' score of 1.43 indicating that BioAtla is being referred to more favorably in the media.

Company	Overall Sentiment
BioAtla	Very Positive
Cellectar Biosciences	Positive

Summary

BioAtla beats Cellectar Biosciences on 8 of the 14 factors compared between the two stocks.

How does BioAtla compare to Novogen?

Novogen (NASDAQ:KZIA) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Novogen has higher earnings, but lower revenue than BioAtla.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	785.40	-$13.41M	N/A	N/A
BioAtla	$2M	3.20	-$59.61M	-$41.72	N/A

In the previous week, Novogen had 2 more articles in the media than BioAtla. MarketBeat recorded 3 mentions for Novogen and 1 mentions for BioAtla. BioAtla's average media sentiment score of 1.87 beat Novogen's score of 0.96 indicating that BioAtla is being referred to more favorably in the news media.

Company	Overall Sentiment
Novogen	Positive
BioAtla	Very Positive

Novogen has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
BioAtla	N/A	N/A	-325.64%

30.9% of Novogen shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 1.0% of Novogen shares are held by company insiders. Comparatively, 9.3% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Novogen currently has a consensus price target of $23.75, suggesting a potential upside of 66.32%. BioAtla has a consensus price target of $200.00, suggesting a potential upside of 5,081.35%. Given BioAtla's higher possible upside, analysts plainly believe BioAtla is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Novogen beats BioAtla on 7 of the 12 factors compared between the two stocks.

How does BioAtla compare to Tempest Therapeutics?

BioAtla (NASDAQ:BCAB) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

In the previous week, BioAtla and BioAtla both had 1 articles in the media. BioAtla's average media sentiment score of 1.87 equaled Tempest Therapeutics'average media sentiment score.

Company	Overall Sentiment
BioAtla	Very Positive
Tempest Therapeutics	Very Positive

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 9.3% of BioAtla shares are owned by company insiders. Comparatively, 36.3% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Tempest Therapeutics has lower revenue, but higher earnings than BioAtla. Tempest Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	3.20	-$59.61M	-$41.72	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

BioAtla's return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-325.64%
Tempest Therapeutics	N/A	-355.61%	-121.21%

BioAtla has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.85, indicating that its share price is 285% less volatile than the broader market.

BioAtla presently has a consensus target price of $200.00, suggesting a potential upside of 5,081.35%. Given BioAtla's stronger consensus rating and higher probable upside, research analysts plainly believe BioAtla is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

BioAtla beats Tempest Therapeutics on 8 of the 12 factors compared between the two stocks.

How does BioAtla compare to Exicure?

Exicure (NASDAQ:XCUR) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

BioAtla's return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
BioAtla	N/A	N/A	-325.64%

BioAtla has a consensus price target of $200.00, suggesting a potential upside of 5,081.35%. Given BioAtla's stronger consensus rating and higher probable upside, analysts clearly believe BioAtla is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Exicure had 4 more articles in the media than BioAtla. MarketBeat recorded 5 mentions for Exicure and 1 mentions for BioAtla. BioAtla's average media sentiment score of 1.87 beat Exicure's score of 0.57 indicating that BioAtla is being referred to more favorably in the news media.

Company	Overall Sentiment
Exicure	Positive
BioAtla	Very Positive

42.8% of Exicure shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 52.8% of Exicure shares are held by company insiders. Comparatively, 9.3% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Exicure has a beta of 3.53, suggesting that its stock price is 253% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Exicure has higher earnings, but lower revenue than BioAtla. Exicure is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	35.42	-$4.95M	-$1.55	N/A
BioAtla	$2M	3.20	-$59.61M	-$41.72	N/A

Summary

BioAtla beats Exicure on 8 of the 15 factors compared between the two stocks.

Get BioAtla News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAB vs. The Competition

Export

Metric	BioAtla	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.41M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.09	20.00	24.00	24.42
Price / Sales	3.20	306.76	515.84	118.72
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	-0.14	8.32	10.60	6.82
Net Income	-$59.61M	$23.94M	$3.57B	$337.56M
7 Day Performance	16.62%	1.84%	0.59%	1.16%
1 Month Performance	-9.60%	-0.04%	1.54%	3.16%
1 Year Performance	-80.96%	44.82%	25.41%	30.60%

BioAtla Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAB BioAtla	2.7501 of 5 stars	$3.86 flat	$200.00 +5,081.3%	-81.0%	$6.41M	$2M	N/A	60	Positive News Gap Down
MYNZ Mainz Biomed	N/A	$2.20 -5.6%	N/A	-5.5%	$19.93M	$659.94K	N/A	30	High Trading Volume
CLRB Cellectar Biosciences	4.3953 of 5 stars	$2.40 -4.4%	$11.00 +358.3%	-82.0%	$19.14M	N/A	N/A	10	Positive News
KZIA Novogen	2.2224 of 5 stars	$11.26 -1.2%	$21.00 +86.5%	+53.5%	$18.99M	$30K	N/A	12	Gap Down
TPST Tempest Therapeutics	2.8077 of 5 stars	$1.28 +0.8%	N/A	-80.9%	$18.96M	N/A	N/A	20	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAB) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAtla (BCAB) Competitors

BCAB vs. MYNZ, CLRB, KZIA, TPST, and XCUR

How does BioAtla compare to Mainz Biomed?

Summary

How does BioAtla compare to Cellectar Biosciences?

Summary

How does BioAtla compare to Novogen?

Summary

How does BioAtla compare to Tempest Therapeutics?

Summary

How does BioAtla compare to Exicure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAtla (BCAB) Competitors

BCAB vs. MYNZ, CLRB, KZIA, TPST, and XCUR

How does BioAtla compare to Mainz Biomed?

Does the media prefer MYNZ or BCAB?

Do analysts recommend MYNZ or BCAB?

Which has better valuation and earnings, MYNZ or BCAB?

Is MYNZ or BCAB more profitable?

Which has more volatility & risk, MYNZ or BCAB?

Do institutionals and insiders believe in MYNZ or BCAB?

Summary

How does BioAtla compare to Cellectar Biosciences?

Do institutionals & insiders have more ownership in BCAB or CLRB?

Is BCAB or CLRB more profitable?

Which has higher valuation and earnings, BCAB or CLRB?

Which has more volatility and risk, BCAB or CLRB?

Do analysts recommend BCAB or CLRB?

Does the media favor BCAB or CLRB?

Summary

How does BioAtla compare to Novogen?

Which has preferable earnings and valuation, KZIA or BCAB?

Does the media prefer KZIA or BCAB?

Which has more volatility and risk, KZIA or BCAB?

Is KZIA or BCAB more profitable?

Do institutionals and insiders have more ownership in KZIA or BCAB?

Do analysts rate KZIA or BCAB?

Summary

How does BioAtla compare to Tempest Therapeutics?

Does the media refer more to BCAB or TPST?

Do insiders and institutionals hold more shares of BCAB or TPST?

Which has better earnings & valuation, BCAB or TPST?

Is BCAB or TPST more profitable?

Which has more risk & volatility, BCAB or TPST?

Do analysts rate BCAB or TPST?

Summary

How does BioAtla compare to Exicure?

Is XCUR or BCAB more profitable?

Do analysts rate XCUR or BCAB?

Does the media refer more to XCUR or BCAB?

Do insiders & institutionals hold more shares of XCUR or BCAB?

Which has more volatility & risk, XCUR or BCAB?

Which has preferable valuation & earnings, XCUR or BCAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools